You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Value-Based Reimbursement Decisions for Orphan Drugs: A Scoping Review and Decision Framework
|
|---|---|
| Published in |
PharmacoEconomics, November 2014
|
| DOI | 10.1007/s40273-014-0235-x |
| Pubmed ID | |
| Authors |
Mike Paulden, Tania Stafinski, Devidas Menon, Christopher McCabe |
| Abstract |
The rate of development of new orphan drugs continues to grow. As a result, reimbursing orphan drugs on an exceptional basis is increasingly difficult to sustain from a health system perspective. An understanding of the value that societies attach to providing orphan drugs at the expense of other health technologies is now recognised as an important input to policy debates. |
X Demographics
The data shown below were collected from the profiles of 15 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 7 | 47% |
| United Kingdom | 2 | 13% |
| New Zealand | 1 | 7% |
| Spain | 1 | 7% |
| Unknown | 4 | 27% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 11 | 73% |
| Scientists | 3 | 20% |
| Science communicators (journalists, bloggers, editors) | 1 | 7% |
Mendeley readers
The data shown below were compiled from readership statistics for 197 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 2 | 1% |
| Brazil | 1 | <1% |
| Unknown | 194 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 37 | 19% |
| Student > Master | 34 | 17% |
| Student > Ph. D. Student | 26 | 13% |
| Other | 14 | 7% |
| Student > Postgraduate | 9 | 5% |
| Other | 27 | 14% |
| Unknown | 50 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 42 | 21% |
| Pharmacology, Toxicology and Pharmaceutical Science | 23 | 12% |
| Economics, Econometrics and Finance | 21 | 11% |
| Social Sciences | 13 | 7% |
| Agricultural and Biological Sciences | 8 | 4% |
| Other | 39 | 20% |
| Unknown | 51 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 March 2019.
All research outputs
#3,863,823
of 25,923,151 outputs
Outputs from PharmacoEconomics
#384
of 2,004 outputs
Outputs of similar age
#51,557
of 371,472 outputs
Outputs of similar age from PharmacoEconomics
#7
of 26 outputs
Altmetric has tracked 25,923,151 research outputs across all sources so far. Compared to these this one has done well and is in the 85th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,004 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.7. This one has done well, scoring higher than 80% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 371,472 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 26 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.